MedTrace Logo

Prognosis Related to Induced Thrombopenia With Heparin Under Venoarterial ECMO in Reanimation

NCT03979625 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2019-06-07

No results posted yet for this study

Summary

Thrombocytopenia is a frequent and serious adverse event in patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock. Similarly to postcardiac surgery patients, heparin-induced thrombocytopenia (HIT) could represent the causative underlying mechanism. However, the epidemiology as well as related mortality regarding HIT and VA-ECMO remains largely unknown. The investigators aimed to define the prevalence and associated 90-day mortality of HIT diagnosed under VA-ECMO.This retrospective study included patients under VA-ECMO from 20 French centers between 2012 and 2016.

Conditions

  • Heparin-induced Thrombocytopenia

Interventions

OTHER

Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies

Patients are classified according to results of functional tests as having either Confirmed or Excluded HIT.

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2018-04-30
Completion
2018-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03979625 on ClinicalTrials.gov